People

The power of our transpacific partnerships lies at the heart of our investment and company building strategy. We leverage an extensive global network as well as an &#8220;on-the-ground&#8221;, local presence in both Japan and the United States. This enables us to access differentiated sourcing and early-stage investment opportunities for the creation and development of bespoke new biotech companies on both sides of the Pacific. Through this approach, the team gains insights and perspectives that enable it to maximize therapeutic impact for patients around the world, while generating attractive risk-adjusted returns for investors.

Catalys Pacific maximizes its profound global network and robust local presence in Japan to propel its mission of improving patient lives. It is an honor to be a part of that mission.”

Transforming Life Sciences Innovation By Creating And Investing In Global Companies

Catalys Pacific

Home

Acquired

Acquired Archives - Catalys Pacific

Casey Logan

CBO at Travere Therapeutics, Inc.

Renalys Pharma is a private, late-stage clinical biopharmaceutical company committed to the development of innovative therapeutics that address unmet needs in the management of renal disease. It was co-founded by Catalys Pacific and SR One. Renalys’ current efforts are centered on bringing sparsentan, an investigational dual-acting treatment developed by Travere Therapeutics, to patients in Japan as well as other Asian countries more broadly.

Catalyst to access novel therapies for Asian patients with renal disease

Renalys - Catalys Pacific

Renalys

Masayuki Takayanagi

CEO at Fuji Yakuhin Co., Ltd.

Crystalys Therapeutics (“Crystalys”) is a private, late-stage clinical biopharmaceutical company co-founded by Catalys Pacific and Novo Holdings to pioneer the development of best-in-class treatment for patients suffering with gout. Crystalys’ current efforts are centered on bringing Dotinurad, an urate transporter (“URAT1”) inhibitor approved in Japan, to patients outside of Japan experiencing inadequate response to urate lowering therapies (“ULT”).

Catalyzing Development of Best-in-class Treatment for Patients with Gout

Home

Creations

Renalys

Crystalys